Time filter

Source Type

Oncotest Gmbh and PIRAMAL LIFE science Ltd | Date: 2010-11-15

The present invention provides compounds represented by formula (1): wherein, R

Piramal Life science Ltd | Date: 2010-06-30

Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CR

The present invention provides novel compounds represented by the general formula (I): their stereoisomers, pharmaceutically acceptable salts and their pharmaceutically acceptable solvates thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The invention also relates to a process for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them.

Piramal Life science Ltd | Date: 2010-08-11

Compounds of formula 1: are disclosed, wherein V is CH

PIRAMAL LIFE science Ltd | Date: 2010-12-09

The present invention relates to a method employing Interferon Epsilon (IFNE1) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment involving the use of cyclin dependent kinase (CDK) inhibitors. The inventors have identified IFNE1 as a biomarker transcript that is upregulated when cancer cells are treated with CDK inhibitors. In an embodiment, the method of the invention includes measuring a level of IFNE1 mRNA or IFNE1 protein in a subjects tumor, blood or other tissue. An increase in the level of IFNE1 compared to control level can indicate that the CDK inhibitor has produced a therapeutic response or can determine whether a tumor is sensitive to a CDK inhibitor.

Discover hidden collaborations